Skip to main content
SpringerLink
Log in

Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) play important roles in progression of chronic heart failure (HF) by regulating cardiac extracellular matrix metabolism. However, there is no report to investigate the difference of circulating MMP-1 and MMP-2 levels between systolic HF (SHF) and diastolic HF (DHF), particularly in light of acute exacerbation of HF. We assessed 110 HF patients who were admitted because of an acute exacerbation. They were divided into two groups: SHF [n = 68, left ventricular ejection fraction (LVEF) <45%] or DHF (n = 42, LVEF ≥45%). Ten patients without HF served as controls. Serum MMP-1 and MMP-2, and plasma brain natriuretic peptide (BNP) levels were examined on admission and at discharge. Serum MMP-1 level was higher on admission in both SHF and DHF than in controls. It was higher in SHF than in DHF and did not change at discharge in both groups. Serum MMP-2 level was equally higher on admission in SHF and DHF than in controls. It decreased in both groups at discharge. Treatment-induced changes in LVEF and BNP level correlated with those in MMP-2 level in SHF but not in DHF. Circulating MMP-1 and MMP-2 levels showed different dynamics between SHF and DHF in acute exacerbation and after treatment. These differences in circulating MMP-1 and MMP-2 levels may be related to the phenotype of HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Spinale FG (2002) Matrix metalloproteinases: regulation and dys-regulation in the failing heart. Circ Res 90:520–530

    Article  PubMed  CAS  Google Scholar 

  2. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L (1998) Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82:482–495

    PubMed  CAS  Google Scholar 

  3. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ (2000) A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102:1944–1949

    PubMed  CAS  Google Scholar 

  4. Fujiwara T, Matsunaga T, Kameda K, Abe N, Ono H, Higuma T, Yokoyama J, Hanada H, Osanai T, Okumura K (2007) Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels 22:303–307

    Article  PubMed  Google Scholar 

  5. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494

    Article  PubMed  CAS  Google Scholar 

  6. Harper J, Harper E, Covell JW (1993) Collagen characterization in volume-overload- and pressure-overload-induced cardiac hypertrophy in minipigs. Am J Physiol 265:H434–H438

    PubMed  CAS  Google Scholar 

  7. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG (2002) Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8:390–398

    Article  PubMed  CAS  Google Scholar 

  8. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Arnold M, Demers C, McKelvie RS, Liu PP (2006) Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12: 514–519

    Article  PubMed  CAS  Google Scholar 

  9. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150:484–487

    Article  PubMed  CAS  Google Scholar 

  10. Tziakas DN, Chalikias GK, Papaioakeim M, Hatzinikolaou EI, Stakos DA, Tentes IK, Papanas N, Kortsaris A, Maltezos E, Hatseras DI (2005) Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 96: 1449–1451

    Article  PubMed  CAS  Google Scholar 

  11. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH, Baker AJ (2006) Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 69:688–696

    Article  PubMed  CAS  Google Scholar 

  12. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH (2007) Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292:H1847–H1860

    Article  PubMed  CAS  Google Scholar 

  13. Abou-Raya S, Naim A, Marzouk S (2004) Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clin Invest Med 27:93–100

    PubMed  CAS  Google Scholar 

  14. López B, González A, Querejeta R, Larman M, Díez J (2006) Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48:89–96

    Article  PubMed  Google Scholar 

  15. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D’Armiento J (2000) Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 106:857–866

    Article  PubMed  CAS  Google Scholar 

  16. Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105:1387–1393

    Article  PubMed  Google Scholar 

  17. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP (2002) Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288:2144–2150

    Article  PubMed  Google Scholar 

  18. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K(2007) Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115:888–895

    Article  PubMed  Google Scholar 

  19. Zhang J, Fujimoto N, Iwata K, Sakai T, Okada Y, Hayakawa T (1993) A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies. Clin Chim Acta 219:1–14

    Article  PubMed  CAS  Google Scholar 

  20. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T (1993) A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 221:91–103

    Article  PubMed  CAS  Google Scholar 

  21. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367

    PubMed  CAS  Google Scholar 

  22. Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davidson TW, Davis JL, Douglas PS, Gillam LD (1997) ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 95:1686–1744

    PubMed  CAS  Google Scholar 

  23. How to diagnose diastolic heart failure (1998) European Study Group on Diastolic Heart Failure. Eur Heart J 19:990–1003

    Google Scholar 

  24. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G (2003) Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33:648–656

    Article  PubMed  CAS  Google Scholar 

  25. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T, Takeda H, Hori M, Masuyama T (2003) Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 57:766–774

    Article  PubMed  CAS  Google Scholar 

  26. Siwik DA, Chang DL, Colucci WS (2000) Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86:1259–1265

    PubMed  CAS  Google Scholar 

  27. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr (2002) Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91:1127–1134

    Article  PubMed  CAS  Google Scholar 

  28. Banfi C, Cavalca V, Veglia F, Brioschi M, Barcella S, Mussoni L, Boccotti L, Tremoli E, Biglioli P, Agostoni P (2005) Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J 26:481–488

    Article  PubMed  CAS  Google Scholar 

  29. Senzaki H, Gluzband YA, Pak PH, Crow MT, Janicki JS, Kass DA (1998) Synergistic exacerbation of diastolic stiffness from shortterm tachycardia-induced cardiodepression and angiotensin II. Circ Res 82:503–512

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan

    Yoshiro Naito, Takeshi Tsujino, Masaaki Lee-Kawabata, Mika Matsumoto, Akira Ezumi, Shinji Nakao, Akiko Goda & Tohru Masuyama

  2. Division of Coronary Heart Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

    Mitsumasa Ohyanagi

Authors
  1. Yoshiro Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Tsujino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaaki Lee-Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mika Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akira Ezumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinji Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akiko Goda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitsumasa Ohyanagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tohru Masuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tohru Masuyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naito, Y., Tsujino, T., Lee-Kawabata, M. et al. Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction. Heart Vessels 24, 181–186 (2009). https://doi.org/10.1007/s00380-008-1100-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-008-1100-7

Key words

Search

Navigation